Losartan and Renal failure: is the FAERS signal real?
Losartan ↔ Renal failure
Losartan is the prototype angiotensin-receptor blocker, and its renal effects mirror the class: reduced efferent-arteriolar tone and filtration pressure can precipitate or worsen renal failure (3,053 co-reports, PRR 2.8), particularly with volume depletion, bilateral renal-artery stenosis, or combined NSAID use. The signal is dominated by the drug's very large prescribing base rather than a property unique to losartan, and function usually recovers after the drug or precipitant is withdrawn.
Regulatory basis: losartan prescribing information — renal impairment; class effect of RAAS blockade.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Creatinine rises after initiation |
| Strength | met | PRR 2.8, modest |
| Consistency | met | Consistent across the ARB class |
| Specificity | partial | Shared with ACE inhibitors and ARBs |
| Biological gradient | met | Worse with volume depletion |
| Plausibility | met | Consequence of RAAS blockade |
| Coherence | met | Fits the mechanism |
| Experiment | n/a | Not tested as a trial endpoint |
| Analogy | met | Analogous to ACE-inhibitor renal effects |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.